US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

49.28

-0.1000-0.20%

Post-market: 49.280.00000.00%19:30 EDT

Volume:381.48K

Turnover:18.76M

Market Cap:15.07B

PE:22.10

High:49.32

Open:48.96

Low:48.66

Close:49.38

52wk High:55.49

52wk Low:45.78

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.45

T/O Rate:0.12%

Dividend:2.09

Dividend Rate:4.24%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.63

PE(LYR):19.99

Loading ...

Overview Company News Filings

Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

AmChamSG Recognizes Inaugural Green Planet Champions

S&P 500 Futures Decline In Premarket Trading; Magnum Ice Cream, Figma Lead

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

EMA Partners Appoints Alicia Yi as Group Executive Advisor, Strengthening Executive Search & Leadership Advisory Capabilities Across APAC

Press Release: Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Press Release: LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Emera price target raised to C$74 from C$73 at CIBC

Press Release: GENFIT Annual Combined General Meeting of June 15, 2026 -- Availability of Preparatory Documents

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN)

Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe

MT Newswires Live

Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial

Emera (EMA) Receives a Hold from Barclays

Press Release: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Emera Q1 Adjusted Earnings, Revenue Rise

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/EMA/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.28,"timestamp":1789761600000,"preClose":49.38,"halted":0,"volume":381479,"hourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0020251113811259906,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":-0.1,"latestTime":"09-18 16:00:00 EDT","open":48.96,"high":49.32,"low":48.66,"amount":18759191.6771,"amplitude":0.013366,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":49.38,"dividendRate":0.042791,"postHourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4540410074543813,"impliedVol":0.4231,"impliedVolPercentile":0.9761},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.4540410074543813,"shares":305783111,"dividePrice":2.087723,"high":49.32,"amplitude":0.013366,"preClose":49.38,"low":48.66,"week52Low":45.78,"pbRate":"1.63","psRate":"2.36","week52High":55.49,"institutionHeld":0,"latestPrice":49.28,"eps":2.229761,"divideRate":0.042365,"volume":381479,"delay":0,"ttmEps":2.229761,"open":48.96,"prevYearClose":49.24,"prevWeekClose":49.19,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":49.19,"twentyDayClose":51.78,"sixtyDayClose":52.9,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-18","current":22.101023,"percent":0.558282,"low":16.637027,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"high":22.07626,"avg":19.830871,"sd":1.467509,"marketCap":15149228130.36},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36}],"updateTime":1789897001227},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636085515","title":"Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2636085515","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636085515?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial. NEW YORK, May 19, 2026 /PRNewswire/ --  May 19, 2026 -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000.The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69. Investors will also receive 120% warrant coverage with an exercise price of $1.45 per share and a five-year term from the date of issuance. Two of the private placements for an aggregate of $200,000 in gross proceeds closed on May 11, 2026; the final May private placement closed on May 18, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU2089283258.USD","LU0106261372.USD","LU1064131342.USD","BK4139","LU1162221912.USD","LU0882574139.USD","BK4007","LU2111349929.HKD","LU1732800096.USD","LU0528227936.USD","LU1720051108.HKD","LU0053666078.USD","LU1989772840.SGD","BK4232","LU0795875169.SGD","LU0971096721.USD","LU2357305700.SGD","BCLI","LU1720051017.SGD","BK4127","LU1988902786.USD","LU0158827948.USD","LU1244550494.USD","LU1244550577.SGD","LU0158827781.USD","BK4022","BK4539","LU0267386448.USD","LU2089284900.SGD","LU0106831901.USD","LU0390134368.USD","BK4534","LU1548497426.USD","R","LU2264538146.SGD","BK4516","IE00BKVL7J92.USD","LENZ","BK4588","LU1791710400.SGD","LU0795875086.SGD","LU0006306889.USD","LU0210528500.USD","BK4081","LU1244550221.USD","EMA","IE00BZ1G4Q59.USD","BK4504","LU0912757837.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853691","title":"AmChamSG Recognizes Inaugural Green Planet Champions","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853691","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636853691?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:21","pubTimestamp":1779189660,"startTime":"0","endTime":"0","summary":"2026 AmChamSG Green Planet Energy Forum celebrates leadership and commitment to advancing a more sustainable and resilient energy future.SINGAPORE, May 19, 2026 /PRNewswire/ -- The American Chamber of Commerce in Singapore  recognized the inaugural Green Planet Champions at the 2026 AmChamSG Green Planet Energy Forum on Friday, May 15, 2026, with Guest of Honor Dr. Tan See Leng, Minister for Manpower and Minister-in-charge of Energy and Science & Technology, Ministry of Trade and Industry.During the fireside chat, Minister Tan discussed Singapore's journey in energy transition and how Singapore has managed energy security amid geopolitical developments and global uncertainties.About AmCham Singapore Established in 1973, the American Chamber of Commerce in Singapore  is the largest and the most active international business association in Singapore and Southeast Asia, with over 600 American and other global companies with significant U.S. business interests. AmChamSG is an independent, ","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2983129/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2983129/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/amchamsg-recognizes-inaugural-green-planet-champions-302776090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7129","BK4081","EMA","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089981","title":"S&P 500 Futures Decline In Premarket Trading; Magnum Ice Cream, Figma Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089981","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089981?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Magnum Ice Cream Co. N.V.  was up 13.1% in pre-market trading, and Figma Inc. Cl A  was up 10.6%.Broadridge Financial Solutions Inc. , Celanese Corp. , and Emera Inc.  were all posting gains of at least 4%. In early trading, Vicor Corp.  and Enlight Renewable Energy Ltd.  had posted declines, falling 6.2% and 6.2%, respectively.Meanwhile S&P 500 futures were down 0.83%, with futures for the Dow Jones Industrial Average falling 0.47%. The Cboe Volatility Index futures were up 8.62%.In commodities news, Brent crude oil futures were up 2.01%, while gold futures were down 2.48%. Bitcoin was down 1.02% to $80,603.In the previous regular trading session, the S&P 500 and the Dow were up 0.77% and 0.75%, respectively. Stocks in Asia were down overnight, with Japan's NIKKEI 225 Index down 1.99% and China's Shanghai Composite Index falling 1.02%.In af","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPYG","IE0034235188.USD","MMAX","OEF","ITOT","IVW","SH","MESmain","GPIX","SPHD","XDTE","SMAX","CE","SPLV","DBSC","SSO","IJH","IJR","NOBL","BK4504","LU1228905037.USD","ENLT","EMA","BR","TSPY","SPYH",".SPX","SPUU","SCHB","LU0390134368.USD","BK4585","RSPN","SPYM","BK4096","MOAT","XYLD","BMAY","VICR","SPUS","BK4109","OEX","SPYQ","SPYI","BK4133","VTI","UPRO","SPXL","RSPU","IVE",".DJI","ESmain","SPDN","GSLC","VBK","SFY","HIBL","XLG","SPYD","SPYB","DMAX","RSP","HIBS","YSPY","SPYV","BK4534","FIG","IE0009354923.USD","SPXS","BK4581","LU1228905540.USD","SDS","BK4548","DJX","JEPI","RSPA","SPYU","BK4226","SCHX","SPXU","IVV","BK4588","SPGP","BK4550","MICC","BK4023","BK4559","FIGG","ALLW","SPMO","LU0545562505.USD","BK4081","VV","ACWI","ETFT","BK4212","VEU","BK4106","VTV","SPHQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088937","title":"Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088937","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088937?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:01","pubTimestamp":1778839260,"startTime":"0","endTime":"0","summary":"All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295666/0/en/Positive-Interim-Data-from-Cohorts-1-and-2-of-Tenaya-s-RIDGE-1-Phase-1b-2-Clinical-Trial-of-TN-401-Demonstrated-Consistent-Reductions-in-Arrhythmia-Burden-for-Adults-with-PKP2-asso.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ECG","EMA","BK4585","TNYA","BK4588","BK4539","BK4139","LU1559883803.SGD","BK4007","HCM","LU0566484027.USD","BK4531","BK4081","BK4129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746529","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635746529?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:47","pubTimestamp":1778770020,"startTime":"0","endTime":"0","summary":"-- Updated positive data from iadademstat in 1L AML unfit patients to be. presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract. -- Ongoing broad expansion of iadademstat clinical development across. PORTICO-2 Phase III trial with vafidemstat in aggression in BPD. -- Strong cash position at the quarter ended March 2026: $25.4 million. \"The iadademstat development platform continues to expand, reinforcing its potential as a high-value hematology and oncology asset,\" Dr. Buesa continued. \"Enrollment is advancing across multiple investigator-sponsored studies at leading U.S. cancer centers and National Cancer Institute-sponsored trials in hematologic malignancies and solid tumors. At the same time, em","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4144","PTA","BK4081","NCI","ET","ORR","BK4561","BK4585","BK4588","BK4161","BK4581","BK4590","SCD","CR","BK4202"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635899437","title":"Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635899437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635899437?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:11","pubTimestamp":1778670660,"startTime":"0","endTime":"0","summary":"CARDAMYST (etripamil) nasal spray launch for PSVT isgaining traction; breadth of unique prescribers supportspotential future adoptionExpress Scripts national formulary coverage secured as company make","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293867/0/en/Milestone-Pharmaceuticals-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","ECG","BK4215","BK4081","LU0566484027.USD","BK4585","AV","BK4588","MAA","LU1559883803.SGD","BK4129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635882276","title":"EMA Partners Appoints Alicia Yi as Group Executive Advisor, Strengthening Executive Search & Leadership Advisory Capabilities Across APAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2635882276","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635882276?lang=en_us&edition=fundamental","pubTime":"2026-05-13 12:01","pubTimestamp":1778644860,"startTime":"0","endTime":"0","summary":"SINGAPORE, May 13, 2026 /PRNewswire/ -- Global executive search and leadership advisory firm EMA Partners today announced that former Korn Ferry Vice Chair Alicia Yi has joined the firm as Group Executive Advisor, based in Singapore.Her appointment comes as organisations across Asia-Pacific navigate increasing complexity in leadership — from CEO succession and board composition to accelerating digital and AI-driven transformation. Across the region, companies are placing greater emphasis on senior-led, advisory-driven engagement to support critical leadership decisions, particularly as Singapore continues to strengthen its role as a regional hub for leadership decision-making across Asia-Pacific and ASEAN.Alicia began her career in human capital consulting at Towers Perrin in Singapore and Chicago, before taking on an international HR leadership role at Swiss Bank Corporation in Zurich. Her cross-border and multidisciplinary background has made her a sought-after advisor on CEO success","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ema-partners-appoints-alicia-yi-as-group-executive-advisor-strengthening-executive-search--leadership-advisory-capabilities-across-apac-302770361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","AESC","BK4581","APAC","IWF","BK4585","EMA","BK4105","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635280247","title":"Press Release: Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635280247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635280247?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:08","pubTimestamp":1778616480,"startTime":"0","endTime":"0","summary":"- Duchenne : First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program's global development -. - Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -. - Friedreich's Ataxia : Second participant dosed in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated with no serious adverse events observed -. - CPVT : Company anticipates dosing the first participant in the Phase 1b ARTEMIS clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia  in H2 2026 -. \"In parallel, we are working closely with the UK Medic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4604","BK4099","BK4130","TM","03160","PIP","BK4081","BK4201","BK4585","SLDB","BK4555","BK4139","EMA","EC","BK4588","FA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634521637","title":"BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1","url":"https://stock-news.laohu8.com/highlight/detail?id=2634521637","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634521637?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585400,"startTime":"0","endTime":"0","summary":"- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-sp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292712/0/en/BridgeBio-Submits-NDA-to-FDA-for-Encaleret-for-Individuals-Living-with-ADH1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","EMA","BK4585","BK4588","BK4081","BK4215","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232265","title":"Press Release: LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232265?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529900,"startTime":"0","endTime":"0","summary":"Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ product sales. Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026. Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026. Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT. SAN DIEGO, May 11, 2026  -- LENZ Therapeutics, Inc. , a pharmaceutical company focused on the commercialization of VIZZ  1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the first quarter ended March 31, 2026 and recent corporate highlights.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4232","LENZ","MAA","BK4007","BK4539","EMA","BK4022","R","BK4588","BK4139","BK4215","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634231804","title":"Emera price target raised to C$74 from C$73 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2634231804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634231804?lang=en_us&edition=fundamental","pubTime":"2026-05-12 02:06","pubTimestamp":1778522774,"startTime":"0","endTime":"0","summary":"CIBC raised the firm’s price target on Emera (EMA) to C$74 from C$73 and keeps a Neutral rating on the shares. Published first on TheFly – the ulti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c74-from-c73-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c74-from-c73-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634605236","title":"Press Release: GENFIT Annual Combined General Meeting of June 15, 2026 -- Availability of Preparatory Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2634605236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634605236?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:00","pubTimestamp":1778518800,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , May 11, 2026 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 French legal announcements bulletin ndeg56  the notice of the Combined Shareholders Meeting, which will be held on June 15, 2026, at 10:00 am , at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.All documentation regarding this Combined Shareholders' Meeting will be available to shareholders in accordance with existing regulations on the Company's website, in the Financials section under the Combined Shareholders Meeting tab .The Combined Shareholders' Meeting will be broadcasted live and will be available on the Company's website in the same section. A recording of the Combined Shareholders' Meeting will be available on the Company's website within the time frame specified by regulatio","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4588","03160","BK4585","BK4022","CCA","R","TM","USA","CET","BK4132","BK4081","BK4099","PBC","BK4555","EMA","BK4232","AD","HE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634821492","title":"Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821492","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821492?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:30","pubTimestamp":1778506200,"startTime":"0","endTime":"0","summary":"-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated prof","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291995/0/en/Acoramidis-Continues-to-Demonstrate-Disease-Modifying-Effects-in-ATTR-CM-Reducing-sTTR-Variability-and-Outpatient-Worsening-Heart-Failure.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2298064838.USD","LU1939255532.USD","LU0689626769.HKD","LU2308191902.HKD","ATTR","LU0124676726.USD","BK4081","BK4516","LU2244417387.USD","LU1861214812.USD","LU2360107325.USD","CM","ACM","LU1861219969.SGD","BK4129","BK4207","LU2238339852.HKD","LU0187121727.USD","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285232","title":"Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634285232?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:40","pubTimestamp":1778499650,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Utilities sector with new ratings on Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN). Emer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-ppl-ppl-and-algonquin-power-utilities-aqn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-ppl-ppl-and-algonquin-power-utilities-aqn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AQNB","BK4585","EMA","IE00BBT3K403.USD","LU1093756168.USD","IE00BLSP4452.SGD","BK4081","IE00BN8TJ469.HKD","LU1093756325.SGD","IE00BD4GTV84.USD","LU0320765489.SGD","LU2449327464.USD","AQN","IE00BD4GTT62.SGD","IE00BLSP4239.USD","PPL","LU0683600562.USD","BK4588","LU0787776722.HKD","LU0208291251.USD","IE00BD4GTW91.USD","LU0070302665.USD","BK4208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634780283","title":"Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2634780283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634780283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498424,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","BK1161","EMA.AU","BK7129","06938","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634828842","title":"Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634828842","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634828842?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"-- Elraglusib oral tablet formulation to drive next-phase clinical. -- FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer. patients, with focus on metastatic melanoma, NSCLC, colorectal, and. pancreatic cancers with initiation planned for 2H 2026. To support this initiative, the Company recently received Investigational New Drug  clearance from FDA to conduct a Phase 1/2 study designed to demonstrate that a higher overall exposure to elraglusib can be achieved with the oral formulation compared to the IV formulation. The study will evaluate the safety and potential efficacy of the oral formulation as a monotherapy in solid tumor patients, including those with metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, based on evidence of efficacy of the IV formulation in prior clinical studies and machine learning therapeutic target analyses.\"Advancing the elraglusib oral tablet is an important element to the success of our overall development strategy,\" sai","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","PK","BK4548","IE00B5TLWC47.USD","BK4588","LABU","LU2413666699.HKD","BK4121","ACTU","LU0347712357.USD","IND","IE00BYQQ9H92.USD","BK4218","LU2413666426.HKD","LU1093756325.SGD","BK4181","LU2211817866.USD","EMA","BK4585","BK4567","IE00BFXG0V08.USD","LU1093756168.USD","BK4081","LU1721428933.USD","MTD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634050407","title":"Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634050407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634050407?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:12","pubTimestamp":1778494370,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. Class H ( ($HK:6938) ) has provided an update. Suzhou Ribo Life Science has submitted a phase 2b clinical trial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-vortosiran-with-ema-filing-for-phase-2b-vte-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-vortosiran-with-ema-filing-for-phase-2b-vte-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634840658","title":"Emera (EMA) Receives a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2634840658","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634840658?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:00","pubTimestamp":1778486409,"startTime":"0","endTime":"0","summary":"In a report released today, Michael Lonegan from Barclays maintained a Hold rating on Emera, with a price target of $52.00. According to TipRanks, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/emera-ema-receives-a-hold-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/emera-ema-receives-a-hold-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633535974","title":"Press Release: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633535974","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633535974?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:30","pubTimestamp":1778239800,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended March 31, 2026.\"We remain disappointed with the unanticipated outcome of the FLASH2  study,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \"Despite the fact that HyBryte  demonstrated statistically significant reductions in cutaneous T-cell lymphoma  lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study. Over the coming weeks, we will analyze the data to better determine why the study did not meet expectations. If there is any clarity gained from further analysis of the dataset, especially with respect to specific subsets of patients that may benefit from HyBryte therapy, then w","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4168","BK4081","BK4099","BK4585","R","SNGX","03160","BK4022","BK4588","BK4604","IDR","PIM","BK4139","TM","BK4232","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432748","title":"Emera Q1 Adjusted Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432748","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432748?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236298,"startTime":"0","endTime":"0","summary":"Emera  reported Q1 adjusted earnings Friday of 1.37 Canadian dollars  per share, up from CA$1.28 a year earlier.Analysts polled by FactSet expected CA$1.20.Revenue for the quarter ended March 31 was CA$2.81 billion, up from CA$2.68 billion a year earlier.Three analysts polled by FactSet expected CA$2.42 billion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA.AU","BK7129","EMA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}